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Summary 
Lymphocyte recognition of antigen by the  antigen-specific T  cell  receptor  (TCR.)  and core- 
ceptor complexes rapidly alters the cell's adhesive properties facilitating high avidity cell-ligand 
interactions necessary for lymphocyte development and function. Here,  we report the expres- 
sion  of CD81  (target  of antiproliferative  antigen  [TAPA]-I) on human  thymocytes and  the 
physical  association  of CD81  with  CD4  and  CD8  T  cell  coreceptors.  Antibody ligation  of 
CD81 on thymocytes promotes the rapid induction ofintegrin-mediated cell-cell adhesion via 
lymphocyte function-associated molecule-1  (LFA-1). Cross-linking CD81 is also shown to be 
costimulatory with signaling through the TCR/CD3  complex inducing interleukin  2-depen- 
dent  thymocyte  proliferation.  These  data  suggest  that  a  CD81-mediated  pathway  in  thy- 
mocytes is involved in the regulation of both cell adhesion and activation. 
T 
hymic T  cell selection, as well as the activation of ma- 
ture  T  cells,  is  mediated  by  engagement  of MHC- 
peptide  antigen  by the  TCR.  and  its  coreceptors  CD4  or 
CD8  (1-3).  Signals  resulting  from  TCP,.  and  CD4/CD8 
engagerrtent can also influence  the activation state  of inte- 
grins and integrin-ligand  interactions  promote cell-cell  or 
cell-extracellular  matrix  adhesion,  cell  migration,  activa- 
non, and effector functions (4,  5). Integnn-mediated adhe- 
sion to thymic epithelial  and dendritic  cells,  and migration 
of these developing progenitors to cortex, medulla, and pe- 
ripheral  lymphoid  compartments  are  critical  features  of 
normal T  cell development  (6).  However, little  is known 
about  the  molecular mechanisms  that  connect antigen  re- 
ceptor complex-generated signals to the functional activa- 
tion of integrins expressed by thymocytes. 
CD81  is  a  member  of the  recently  described  tetraspan 
family of proteins which play an important role in regulat- 
ing cell adhesion, migration, and cell proliferation mediated 
by integrins (7-10). For example, CD9 associates with very 
late  antigen  (VLA)4 and VLA5  on B  cell progenitors but 
not mature  B  cells,  and it mediates  heterotypic  cell adhe- 
sion to bone marrow stromal fibroblasts  (11).  Another re- 
cently described tetraspan protein,  CD63,  has been shown 
to  associate  with  VLA3  and  VLA6  integrins  (12).  CD81 
was  originally  named  target  of  annproliferative  antigen 
(TAPA-1) because anti-  CD81  antibodies  inhibit  the pro- 
liferation  of many lymphoid cell lines.  CDS1  is  expressed 
on  B  cells  as  part  of the  CD21/CD19/Leu13  complex 
which  is  the  coreceptor  for  the  B  cell  antigen  receptor 
(BCR) and facilitates B  cell activation at low doses of anti- 
gen-C3d  (complement  fragment)  complexes  (9,  13,  14). 
Ligation  of  CD81  on  B  cells  activates  VLA4-mediated 
binding to fibronectin on tonsilar sections  (15).  CD81  has 
been also reported to associate with CD4 and CD8  (core- 
ceptors  for the  TCR)  on T  cell lines  (16,  17).  Although 
CD81  expression  has  been  demonstrated  on  a  variety  of 
lymphoid cell lines,  its expression  and function on human 
thymocytes is  unknown.  The present  report  demonstrates 
the expression of CD81 on thymocytes and its influence on 
thymocyte adhesion and activation. 
Materials  and Methods 
Thymocyte Preparation and Western Blotting.  Thymocytes  were 
prepared by mincing through steel mesh in cold HBSS (GIBCO 
BRL,  Galthersburg,  MD),  purified  over  Flcoll  gradient,  and 
washed two times  in HBSS.  Cells were lysed at  10  s cells/m] in 
1% NP-40, 20 mM Tns,  150 mM NaC1,  4 mM EDTA, 5 ~M 
pepstatin,  1 mM PMSF, 10 p~g/m] leupeptin for l  h on ice, cen- 
trifuged at  14,000 g for 30 nun, and soluble  material  diluted 1:1 
with 2× Laemm]i's without 2-ME. For Western blotting, the cell 
lysates were boiled for 3 min and run on 9% (or 4-10% gradient) 
polyacrylamide gel, transferred to polyvlnyhdine difluoride  (PVDF) 
membranes (Gelman Sciences  Inc., Ann Arbor, MI), blocked in 
5%  BSA/1%  ovalbumin  and  blotted  with  1 Ixg/ml mAb  5A6 
(ant1-CD81).  Proteins were Vlsuahzed by enhanced chemilumi- 
nescence (ECL; Pierce Chenucal Co., Rockford, IL). 
Flow Cytometry.  Thymocytes were  incubated  on ice for 30 
rain in HBSS with 1 I.Lg/m] 5A6 (CD81) or mouse IgG control, 
washed,  and labeled  30 rnin on ice with goat anti-mouse FITC 
conjugate (Fig. 1), or clone CH/4 (CD69) tricolor (Caltag Labo- 
ratones, San Francisco,  CA), anti-CD25 biotin (Olympus Corp., 
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Louis, MO) or with appropriate directly conjugated isotype con- 
trols (Fig.  4  B),  for assessment  on a  FACScan  ® flow cytometer 
(Becton Dickinson  Immunocytometry Systems, San Jose,  CA). 
Data analysis was performed with Winmdi software, available as 
freeware for Windows (http://facs.scripps.edu/software.html). 
Thymocyte Biotinytation.  2  ×  10  s thymocytes/ml in PBS were 
incubated 30 rmn at room temperature with 2  mg/ml sulfosuc- 
cmimidyl-6-(blotinamido) hexanoate  (NHS-LC-Biotm)  (Pierce 
Chemical Co.), washed three times in PBS, and used for lysis. 
bnmunoprecipitation.  150  ~1  of thymocyte lysate at 2  ×  108 
cell equivalents/ml was incubated with 2  p,g of the indicated mAb 
for 2 h at 4°C and then for 2 additional h with rabbit anti-mouse 
adsorbed protein A-Sepharose. Antibodies used were:  UPC-10 
(IgG control), OKT11 (CD2), OKT3 (CD3), OKT4 (CD4), OKT8 
(CD8)  (Amencan Type Culture Collecuon [ATCC], Rockville, 
MD),  5A6  (CD81;  gift of Shoshana Levy,  Stanford Umversity, 
Stanford, CA). Immunopreclpitates were centrifuged at 14,000 g 
for 10 s, washed three times in lysis buffer containing 0.1% detergent, 
resuspended in Laemmh's reagent without 2-ME, run on PAGE, 
and Western blotted as described above. Streptavidin blotting was 
performed  using  1:10,000  dilution  of horseradish  peroxldase- 
conjugated  streptavidln  (Southern Biotechnology Associates, Bir- 
mingham, AL). 
Aggre2ationAssay.  Thymocytes  were  cultured  at  2  ×  105 
cells/well in 96-well culture plates. Inhibition studies were done by 
prelncubanons with the indicated blocking antibodies at 10 Ixg/ml at 
4°C for 30 mm. The precoated cells were then warmed to 37°C 
in a humidified incubator, and 200 ng/ml ofann-CD81  antibody 
were  added.  After  1.5  h  of incubation  the  cells  were  photo- 
graphed.  Blocking annbodles were  antl-VLA-4  (clone  HP2/1; 
gift  of Dr.  Sanchez-Madnd,  The  Pnncess  Hospital,  Madrid, 
Spain),  antl-LFA-1,  and  anti-mtercellular  adhesion  molecule 
(1CAM)-1 (clones 25.3 and 84H10;  Coulter Corp., Hialeah, FL). 
All cultures were done in A1M V serum-free media (GIBCO). As 
control, a mouse anti-rat IgG was used (clone 18.5;  ATCC). All 
cultures were done in AIM V serum-free media. 
Costimulation Assay.  Culture  wells  containing  lmmobihzed 
antibody were precoated overnight with i  txg/ml OKT3 in PBS 
at 4°C,  rinsed, and  coated with  the indicated concentrations of 
anti-CD81  for  4  h  at  37°C.  Soluble  anti-CDS1  antibody was 
added at  the  indicated concentrations in  media  simultaneously 
with the addition of cells. Anti-CD25 (anti-Taq mAb; gift of Dr. 
T.  Waldman  and  Caroline  Goldman,  National  Institutes  of 
Health) was also added simultaneously with cells at the indicated 
concentrations. Cultures were performed in AIM V  serum-free 
media. All coated wells were blocked with heat-aggregated BSA 
(60°C  for  5  mln)  to  cover any remaining binding sites  on  the 
plastic before addition of any soluble antibodies to the cultures. 
Results 
CD81  is expressed at high levels on human  thymocytes 
as determined by Western blotting (Fig. 1 A) and flow cy- 
tometric  analysis  (Fig.  1  B).  Western  blotting  of a  thy- 
mocyte lysate with anti-CD81  results in a single band at the 
expected  size  of 26  kD  under  nonreducing  conditions. 
Flow  cytometric  analysis  demonstrates  that  CD81  is  ex- 
pressed on >99% of all thymocytes, indicating that it is ex- 
pressed at all stages of thymocyte development. 
To  determine  whether  CD81  is  associated with  CD4, 
CD8,  or other surface receptors,  thymocytes were  surface 
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Figure 1.  Demonstration of CD81 expression on human thymocytes. 
Thymocyte lysate was resolved on 4-10% gradient PAGE under nonre- 
ducmg condmons, transferred to a PVDF membrane, and blotted with 
control IgG or with antl-CD81  (mAb 5A6) as indicated (A). Total thy- 
mocytes were  stained with  anu-CD81  or IgG  control  and  goat ann- 
mouse FITC and assessed  by flow cytometry (B)  Data represent experi- 
ments from two thymlc donors 
biotinylated,  lysed  in  (3-[(3-cholamidopropyl)  dimethyl/ 
ammonio]-l-propane-sulfonate)  (CHAPS)  detergent,  im- 
munoprecipitated with antibodies against CD2,  CD3,  CD4, 
CD8,  CD81,  or Ig control, and then analyzed by Western 
blotting with  anti-CD81  (Fig.  2  B).  These  samples  were 
also blotted with  streptavidin to  visuahze  the biotinylated 
target antigen of each immunopreclpitation, as well as co- 
precipitating cell surface molecules  (Fig. 2  A).  The  results 
indicate  that  CD81  is  prominently  associated  with  CD4 
and CD8,  weakly associated with CD3,  and not detectable 
in  association  with  CD2.  The  immunoprecipitation  of 
CD81  and visualization of associated surface proteins reveals 
that CD81  may be also associated with a  number  of other 
cell surface proteins.  None  of these associations were seen 
in  NP-40  lysates (Todd,  S.C.,  S.G.  Lipps, L.  Crisa,  D.R. 
Salomon,  and  C.D.  Tsoukas,  unpublished  observations). 
Note  that  CD81  on  thymocytes is not biotinylated under 
these conditions, and thus is not visualized in the immuno- 
precipitated lysates. 
To  assess whether  CD81  is  capable  of influencing  the 
adhesive properties  of thymocytes,  these  cells were  incu- 
bated  with  anti-CD81  Ab.  Ligation  of thymocyte  CD81 
with as little as 250 ng/ml Ab, without secondary Ab cross- 
hnking,  rapidly induces  (within  1 h  of treatment)  cell-cell 
adhesion resulting in cell aggregation (Fig. 3,  row A). The 
rapid aggregation kinetics suggest that adhesion is mediated 
by the  activation  of preexisting receptors  rather  than  the 
result of new protein synthesis. Culture of thymocytes with 
up to  1,000 ng/ml anti-CD2, -CD3,  -CD4,  or -CD8,  has 
little effect (Fig. 3, row B). This result indicates that aggre- 
gation is not simply a  consequence  of cross-linking highly 
expressed  surface  proteins  thereby  creating  a  bridge  be- 
tween adjacent cells. 
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Figure 2.  CD81 is physically assocmted with CD4  and CD8  on thy- 
mocytes. Thymocytes were surface  biotmylated, lysed in 1% CHAPS, sol- 
uble material was subjected to lmmunopreclpltatxon  as mdmated, resolved 
on  9%  PAGE  under  nonreducmg  condmons,  transferred, and blotted 
with streptavidin (A) or with ann-CD81  (B). Arrows or brackets indicate 
expected molecular weights for  indicated anngens under  nonreducing 
condatmns. Results represent experiments from three thynnc donors. 
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Figure 3.  CD81 hgatmn by anubody induces LFA-l-medlated cell- 
cell adhesion. Thymocytes were cultured with a tltratmn of ann-CD81 
antibody, shown m row A, at 500 ng/ml (AI), 250 ng/ml (A2), 50 ng/ml 
(A3), or 10 ng/ml (A4). Row B shows thymocytes cultured with Abs to 
other highly expressed cell surface protems at 1,000 ng/ml of ann-CD2 
(B1), antl-CD3  (B2), antl-CD4  (B3), or antl-CD8  (B4). Row C shows 
thymocytes treated with  200  ng/ml  ann-CD81  after prior  lncubatmn 
with  10 ~tg/ml rabbit ann-mouse  control (C1), ann-VLA-4 (C2), ann- 
LFA-1 and ann-ICAMq  (C3), or ann-VLA-4,  antl-LFA-I and antl- 
ICAM-1 (C4) In all cases, thymocytes were cultured for 1.5 h and pho- 
tographed. The data represent experiments from three or more thym~c 
donors. 
CD81-induced aggregation does not occur in the absence 
of either Ca  2+  or Mg  2+  or when  cells were maintained at 
4°C  (Todd et al., unpublished observations). Such divalent 
cation and temperature dependence is characteristic ofinte- 
grin-mediated adhesion. Integrins expressed on thymocytes 
include  the  beta-2  family  member  lymphocyte  function- 
associated molecule-1  (LFA)-I, CD11a/CD18)  which  in- 
teracts with the ICAMs of the Ig supergene family, and the 
beta-1 family member VLA-4 (CD49d/CD29)  which serves 
as a receptor for fibronectin and vascular cell adhesion mol- 
ecule-  (VCAM)-I  (18).  To  assess whether  these  integrins 
are  mediating  the  CD81-induced  adhesion,  thymocytes 
were  pretreated  at  4°C  with  blocking  concentrations  of 
specific integrin Abs and then  stimulated with  anti-CD81 
as described above. The results indicate that Ab blocking of 
LFA-1  and  ICAM-1  prevents  aggregation  whereas  anti- 
VLA-4 does not (Fig. 3, row C). Treatment with anti-LFA-1 
alone strongly inhibits aggregation while anti-ICAM-1 alone 
has little effect (Todd,  S.C. et al., unpublished observations). 
This may indicate that LFA-1  is interacting with  ICAM-2 
or ICAM-3, as well as with ICAM-1. 
It is well documented that the conversion of LFA-1 from 
the low to high affinity state results from cell activation and 
is associated with protein kinase C  (PKC)-mediated phos- 
phorylation of the cytoplasmic domains of LFA-1 and adja- 
cent cytoskeletal elements (19-21).  Therefore, we performed 
a series of experiments to determine if PKC activation also 
mediates CD81- induced thymocyte aggregation. First, the 
addition  of phorbol  ester,  PMA  (10  ng/ml)  induces  thy- 
mocyte aggregation within 1 h  which is specifically blocked 
by anti-LFA-1 but not anti-VLA-4 antibodies (Todd, S.C. 
et  al.,  unpublished  observations).  This  result  is  consistent 
with a previous report indicating that LFA-l-mediated ad- 
hesion to thymic epithelial cell lines was induced by PMA 
(22).  Both  anti-CD81  and  PMA-lnduced  aggregation are 
inhibited by the PKC inhibitors calphostin C  and H7 at ap- 
proximate ECs0s  of 250  nM  and  20  IxM,  respectively. In 
contrast, aggregation is not inhibited by the tyrosine kinase 
inhibitor  tyrphostin.  These  findings  implicate  PKC  as  a 
mediator of the CD81  signals that lead to LFA-1 activation. 
The  functionality of CD81  on  thymocytes was  further 
investigated by assessing its capacity to influence cell prolif- 
eranon.  In view of the  antiproliferative effects of anti-CD81 
on lymphoid cell lines, we  assessed its effect on spontane- 
ously proliferating thymocytes. Freshly isolated thymocytes 
contain a population of precursor (CD3  l°) cells that are un- 
dergoing spontaneous  cell division (23).  The  proliferation 
of  these  precursors  in  vivo  generates  a  large  pool  of 
CD4+8 +  cells which  are  the  subjects of thymlc  selection. 
This proliferation can be measured when cells are plated at 
5  ×  10S/well and pulsed overnight with [3H]thymidine. In 
a representative experiment, control IgG treatment yielded 
30,813  -+ 7,757  cpm (mean ±  SD of quadruplicates) while 
cultures  treated  with  anti-CD81  yielded  33,130  _+  8385 
cpm  (mean  ±  SD  of quadruplicates) after 24 h  in culture. 
Similarly,  anti-CD81  did  not  effect  naturally  occurring 
proliferation when measured at 48 h. Thus, proliferation of 
the  naturally  cycling population  of thymocyte  precursors 
does not appear to be inhibited by CD81  binding. 
The ability of CD81  to provide costimulation in concert 
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Figure 4.  Co-cross-hnkmg of CD3 with CD81 stimulates IL-2-medl- 
ated thymocyte prollferanon. (A) Thymocytes were cultured with the ln- 
dlcated concentrations oflmmoblhzed antl-CD81 alone (squares),  or with 
1 wg/ml immoblhzed antl-CD3 and indicated concentrations of soluble 
(not prebound to culture well) antl-CD81 (circles), or with immobilized 
antl-CD3 and indicated amounts of immobilized antl-CD81  (diamonds) 
Cultures, performed in replicates of  four, were pulsed vclth [3H]thymidme 
(1  v,  C1/well) and harvested on day 4 of culture. These results represent 
experiments from two thyrmc donors. (B) Thymocytes  cultured overnight 
(17 h) with media (.fray line),  ann-CD3 alone (dark line),  or anti-CD3 with 
ant1-CD81 (shaded histogram) were analyzed  for CD69 and CD25 expression 
as indicated. (C) Thymocytes  were sumulated with antl-CD3 and anta-CD81 
in the presence ofm&cated concentrations  ofantl-CD25 (Tac) Ab known 
to block the binding of IL-2 to its receptor. Antl-CD3 alone yielded 1,024 
cpm in the experiment shown. 
with CD3 cross-linking was measured as [3H]thymidine in- 
corporation after 4 d in culture. Microtiter plate wells were 
coated with anti-CD3  (1  ~g/ml) and increasing concentra- 
tions ofanti-CD81  (Fig. 4 A). Mternatively, cells were cul- 
tured  with  immobilized  anti-CD3  and soluble  anti-CD81 
(free Ab added to cultures after blocking the plastic surfaces 
to prevent fixation).  The results illustrate  that cross-linking 
of CD3  and  CD81  (both  Abs  fixed  to  the  culture  well) 
promotes a powerful proliferative  response in thymocytes. 
In contrast, immobilized anti-CD3 and soluble anti-CD81, 
immobilized  anti-CD3  alone,  or  immobihzed  anti-CD81 
alone,  have little  effect.  Moreover,  the physical proximity 
of CD81  and  CD3  at the  same  cell surface is required  for 
stimulation.  This  was  demonstrated  by the  lack  of prolif- 
eration  when  anti-CD81-coated  thymocytes were  plated 
onto  immobilized  anti-CD3  and  subsequently  the  CD81 
was  cross-linked  by  addition  of  rabbit  anti-mouse  Ab 
(Todd, S.C. et al.,  unpublished observations). 
Flow cytometrlc analysis of anti-CD3/anti-CD81-stim- 
ulated  thymocytes on  day 3  of culture  demonstrated  that 
76%  are  CD8+CD4 -.  That  proliferation  is  attributed  to 
mature  thymocytes was  expected,  since  these  cells  bear  a 
functionally  competent  TCR/CD3  complex.  We  have 
demonstrated  that this is  the  thymocyte population prolif- 
erating  to  the  combination  of CD3  cross-linking  and  fi- 
bronectin or larninin costimulation (24, 25). 
Thymocytes cultured under the same conditions as those 
in Fig. 4 A  (media, anti-CD3 alone, or anti-CD3 and anti- 
CD81),  were phenotypically characterized for the  expres- 
sion  of the  activation  markers  CD69  and  CD25  (IL-2R). 
Anti-CD3  alone  induces  an  increased  expression  of both 
these  activation  markers  as  early as  17  h  of culture  and 
expression of CD69 is further enhanced by coculture with 
anti-CD81  (Fig.  4  B).  By  day  3,  the  expression  of both 
CD25 and CD69 is substantially  higher on the CD81 costim- 
ulated  thymocytes  which  is  consistent  with  the  observed 
proliferation  in  these  cultures  (not  shown).  Three-color 
flow cytometric analysis after 17 h  of culture demonstrated 
that  in  both  anti-CD3  alone  and  anti-CD3/anti-CD81- 
treated  cultures  the  activated,  CD69 +  cells  are  predomi- 
nantly  CD4-/I°CD8 +.  The  specific  activation  of cells  in 
transition  to  the  mature  CD8+CD4 -  stage  is  consistent 
with  the  expansion  of the  CD4-CD8 +  population  ob- 
served on day 3 in the presence of CD81 cross-linking (not 
shown). 
Despite  the  fact  that  thymocytes  activated  with  either 
anti-  CD3  or anti-CD3/anti-CD81  express  equal levels of 
IL-2R at  17 h, only those cultures costimulated with anti- 
CD81  demonstrate proliferation  (Fig. 4 A).  This suggested 
that CD81-mediated costimulation may be mediated by an 
IL-2-dependent  pathway.  IL-2-dependent  proliferation 
would be  consistent  with  the  increased  IL-21K expression 
observed in the anti-CD3/anti-CD81  activated cells by day 
3.  To test  this  hypothesis,  cells  were  stimulated  with  anti- 
CD3 and anti-CD81  in the presence of increasing amounts 
of a  blocking  anti-IL-2R  Ab.  As  shown  in  Fig.  4,  anti- 
CD3/anti-CD81-stimulated  proliferation  is  inhibited  by 
73% with  500 ng/ml of anti-IL-21K antibody.  Thymocyte 
proliferation is unaffected by control Abs at concentrations 
up to 20 Ixg/ml. 
Discussion 
Lymphocyte recognition  of antigen  rapidly  alters  their 
adhesive state.  Increased adhesion can support higher avid- 
ity interactions  with  APCs  that  may in  turn  facilitate  the 
engagement  and  signaling by other  counterreceptor  pairs. 
Similarly, T  cell development and selection requires TC1K- 
CD4  or  -CD8  recogninon  of MHC-peptide  on  thymic 
epithelial  or dendritic  cells,  and  possibly  other  molecules, 
including  LFA-1.  That  integrin-mediated  adhesion  is  ira- 
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dence that Ab blockade of LFA-1/ICAM-1 interactions in 
mouse fetal thymic organ culture inhibits differentiation of 
CD4-CD8-  cells to CD4+CD8 + cells (26). 
In  the  present  investigation  we  demonstrate  that  a 
CD81-derived signal can regulate thymocyte cell-cell ad- 
hesiveness  through  activation  of the  integrin,  LFA-1.  In 
vivo,  CD81  may  be  activated  directly by  an  unknown 
ligand  or  indirectly as  a  result  of associated receptor  en- 
gagement.  The  latter model allows for the possibility that 
during antigen recognition CD4  or CD8  (or CD21  on B 
cells)  are  engaged  causing  activation  of associated CD81 
molecules which in turn regulate adhesion.  The participa- 
tion of CD81  in the antigen receptor complexes of both T 
and  B  lymphocytes suggests  a  common  fundamental  role 
for CD81  in lymphocyte activation. 
A  recent report has suggested that CD81  is expressed on 
murine thymic epithelium. In that model CD81  serves as a 
ligand  for  an  unidentified  receptor  on  early  thymocytes 
which  promotes  the  differentiation  of CD4-CD8-  cells 
into CD4+CD8 + cells (27). The same report also states that 
fetal mouse thymocytes do not express CD81  (27). In con- 
trast, we demonstrate that CD81  is highly expressed on hu- 
man thymocytes at all stages of maturation (Fig. 1). Recon- 
ciliation of these  data  may  involve  ontogenic  differences 
between  fetal mouse  and  pediatric human  thymus  or ap- 
preciation of important molecular differences between the 
two species in CD81  structure or expression. 
The present report is the first demonstration that CD81 
is expressed on human thymocytes and that the colocaliza- 
tion and cross-linking of CD81  with CD3  on T  cells pro- 
motes  DNA  synthesis.  This  event  does  not  occur  upon 
independent engagement of CD81  or CD3. That prolifera- 
tion is IL-2 mediated suggests that CD81  can provide a co- 
stimulation similar to  that  described for  CD28.  The  data 
presented  here  also  demonstrate  a  novel  functional  rela- 
tionship between  a  tetraspan family member,  CD81,  and 
the activation of the integrin LFA-l-mediating homotyplc 
cell aggregation. In the context ofthymocyte development, 
the regulation of adhesiveness will determine  the location 
of a  cell, the nature  of interactions with neighboring thy- 
mocytes or stromal cells, and its migration within the cor- 
tex or medulla. It will also influence the avidity of the thy- 
mocyte for APCs involved in positive or negative selection. 
Together,  these  findings  support  a  role  for  CD81  in  the 
regulation of thymocyte  adhesion and  activation during 
T  cell development. 
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